0001209191-17-056466.txt : 20171010
0001209191-17-056466.hdr.sgml : 20171010
20171010163508
ACCESSION NUMBER: 0001209191-17-056466
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20171010
FILED AS OF DATE: 20171010
DATE AS OF CHANGE: 20171010
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MOTT DAVID M
CENTRAL INDEX KEY: 0001219871
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38223
FILM NUMBER: 171130852
MAIL ADDRESS:
STREET 1: 1119 ST. PAUL STREET
CITY: BALTIMORE
STATE: MD
ZIP: 21202
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: RHYTHM PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0001649904
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 462159271
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 500 BOYLSTON STREET
STREET 2: 11TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02116
BUSINESS PHONE: 857-264-4280
MAIL ADDRESS:
STREET 1: 500 BOYLSTON STREET
STREET 2: 11TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02116
FORMER COMPANY:
FORMER CONFORMED NAME: RHYTHM METABOLIC, INC.
DATE OF NAME CHANGE: 20150803
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2017-10-10
0
0001649904
RHYTHM PHARMACEUTICALS, INC.
RYTM
0001219871
MOTT DAVID M
1954 GREENSPRING DRIVE
SUITE 600
TIMONIUM
MD
21093
0
0
1
0
Common Stock
2017-10-10
4
C
0
1402870
A
1432248
I
See Note 2
Common Stock
2017-10-10
4
C
0
2927708
A
4359956
I
See Note 2
Common Stock
2017-10-10
4
P
0
550000
17.00
A
4909956
I
See Note 2
Series A Preferred Stoc
2017-10-10
4
C
0
1402870
0.00
D
Common Stock
1402870
0
I
See Note 2
Series A-1 Junior Preferred Stock
2017-10-10
4
C
0
2927708
0.00
D
Common Stock
2927708
0
I
See Note 2
In connection with the closing of the Issuer's initial public offering, each share of the Issuer's series A convertible preferred stock (the "Series A Preferred") and series A-1 junior preferred stock (the "Series A-1 Preferred") converted into the Issuer's common stock on a 9.17-for-one basis without payment or consideration. The Series A Preferred and the Series A-1 Preferred had no expiration date.
The Reporting Person is a director of NEA 13 GP, LTD, which is the sole general partner of NEA Partners 13, L.P. ("NEA Partners 13"). NEA Partners 13 is the sole general partner of New Enterprise Associates 13, L.P. ("NEA 13"), which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 13 shares in which the Reporting Person has no pecuniary interest.
Reflects the number of shares of Series A Preferred and Series A-1 Preferred, as applicable, held by the Reporting Person on an as-converted to common stock basis.
/s/ Sasha Keough, attorney-in-fact
2017-10-10